Company news
Infield Minerals Corp (TSXV:IN) news
Infield Minerals Corp news releases on 6ix. Latest, Dec 23, 2020: ECC Ventures 2 Corp. Qualifying Transaction Target Infield Minerals Expands Land Package…
Press releases — page 2
ECC Ventures 2 Corp. Qualifying Transaction Target Infield Minerals Expands Land Package in Nevada and Announces Additional Board Member
December 23, 2020
ECC Ventures 2 Corp. Definitive Agreement To Acquire Infield Minerals Corp.
December 7, 2020
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
December 3, 2020
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
November 25, 2020
InMed Announces Election of Directors
November 24, 2020
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
November 18, 2020
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
November 16, 2020
ECC Ventures 2 Corp. Enters Letter of Intent with Infield Minerals Corp. for Qualifying Transaction
November 13, 2020
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
November 13, 2020
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
November 12, 2020
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020
November 5, 2020
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020
November 4, 2020
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
September 24, 2020
InMed Pharmaceuticals Announces Additional IntegraSyn(TM) Patent Filing
September 22, 2020
ECC Ventures 2 Announces Termination Of Agreement to Acquire Long Island Beverages
September 15, 2020
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update
September 8, 2020
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020
September 2, 2020
InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
July 7, 2020
InMed Announces Completion of Share Consolidation
June 30, 2020
InMed Introduces IntegraSyn(TM): An Integrated Cannabinoid Manufacturing System
June 24, 2020
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
June 19, 2020
InMed Releases CBN Preclinical Results in Glaucoma
May 27, 2020
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
May 19, 2020
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
May 14, 2020
InMed Files PCT Patent Application for Neuroprotection in Glaucoma
May 12, 2020
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020
May 8, 2020
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference
May 7, 2020
InMed and Almac Group Developing Improved Cannabinoid Production Methods
May 5, 2020
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755
April 30, 2020
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
April 1, 2020
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
March 24, 2020
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak
March 20, 2020
ECC Ventures 2 Announces Amendment to Definitive Agreement to Acquire Long Island Beverages
March 19, 2020
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
March 10, 2020
Edison issues update on InMed Pharmaceuticals (IN)
February 20, 2020
InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
February 14, 2020
InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020
February 7, 2020
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview
January 21, 2020
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials
January 20, 2020
InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress
January 16, 2020
InMed Pharmaceuticals to Present at the Biotech Showcase Conference
January 8, 2020
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa
December 9, 2019
Edison issues update on InMed Pharmaceuticals
November 18, 2019
InMed Pharmaceuticals to Present at the Cowen Conference
November 11, 2019
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
November 8, 2019
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial
November 5, 2019
InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019
November 4, 2019
InMed Pharmaceuticals to Present at the BIO Investor Forum
October 18, 2019
Edison Issues Update on InMed Pharmaceuticals (IN)
September 26, 2019
InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society's annual conference
September 23, 2019